Skopelitou A S, Gloustianou G, Bai M, Huebner K
Department of Pathology, Ioannina University School of Medicine, Ioannina, Greece.
In Vivo. 2001 Mar-Apr;15(2):169-73.
Our purpose was to investigate the expression of FHIT (Fragile Histidine Triad) gene product in a series of 110 urinary bladder TCCs, and its eventual relationship with histological grade, clinical stage, recurrences and patients' survival.
We performed immunohistochemistry in archival material of formalin-fixed, paraffin-embedded tissues, using the anti-Fhit antibody and the Streptavidin-biotin peroxidase method.
In 30 out of 110 cases (27.27%) Fhit protein was absent whereas in 32 cases (29.08%) it was abnormally expressed. In 48 cases (43.63%) Fhit protein was diffusely expressed in all tumor cells. A statistically highly significant correlation (p < 0.001) was noticed between Fhit protein absence or reduction and clinically advanced tumors. Conversely, abnormal Fhit protein expression was not associated with age, histological grade, tumor size, number of recurrences, and clinical outcome in terms of patients' survival.
These results confirm that FHIT gene inactivation is a late event in urinary bladder carcinogenesis. Fhit protein reduced expression or complete absence correlates with advanced clinical stage of the disease, and does not seem to correlate with tumor recurrences and patient survival.
我们的目的是研究脆性组氨酸三联体（FHIT）基因产物在110例膀胱移行细胞癌中的表达情况，以及其与组织学分级、临床分期、复发和患者生存率之间的最终关系。
我们采用抗Fhit抗体和链霉亲和素-生物素过氧化物酶法，对福尔马林固定、石蜡包埋组织的存档材料进行免疫组织化学检测。
110例中有30例（27.27%）未检测到Fhit蛋白，32例（29.08%）出现异常表达。48例（43.63%）中Fhit蛋白在所有肿瘤细胞中弥漫性表达。Fhit蛋白缺失或减少与临床进展期肿瘤之间存在统计学上高度显著的相关性（p < 0.001）。相反，Fhit蛋白异常表达与年龄、组织学分级、肿瘤大小、复发次数以及患者生存方面的临床结局无关。
这些结果证实FHIT基因失活是膀胱癌变过程中的一个晚期事件。Fhit蛋白表达降低或完全缺失与疾病的晚期临床分期相关，似乎与肿瘤复发和患者生存率无关。
